Background
Acute respiratory distress syndrome (ARDS) is a life-threatening condition with an approximate 40% hospital mortality rate [
1], costing 3.6 million hospital days annually in the USA and accounting for 10.4% of intensive care unit (ICU) admissions around the world [
1,
2]. In recent decades, progress has been achieved in the development of possible treatments for ARDS, including protective ventilation strategies, prone positioning, neuromuscular blockade, and extracorporeal membrane oxygenation [
1]. Some pharmacologic compounds have also been suggested to be effective in ARDS prevention [
3]. However, no Food and Drug Administration approved treatment for ARDS is currently available [
4].
ARDS is characterized by uncontrolled inflammation and coagulation with increased capillary permeability, inflammatory cell accumulation in the lung compartments, and pulmonary microvascular coagulopathy [
5]. Platelets play a key role in the pathogenesis and resolution of ARDS as mediators of hemostasis and coagulation, modulators of inflammation and the immune system, and defenders of microbes [
6‐
8]. Antiplatelet therapy can attenuate lung injury by impeding platelet activation and surface adhesion protein expression, such as glycoprotein IIb/IIIa receptor, P-selectin, and intracellular adhesion molecule 1 (ICAM-1) [
9], which is a key step in microvascular thrombus formation and tissue injury [
10,
11]. Platelet inhibition also suppresses the secretion of inflammation mediators such as cytokines, chemokines and granules [
11,
12] and thereby attenuates inflammation in the lung and its interaction with the immune system. Moreover, platelet activation is reported to initiate the innate immune response through pathogen recognition patterns and proinflammatory neutrophil extracellular trap (NET) formation in acute lung injury [
13]. In addition, platelets can produce functional progeny through self-regulation [
14] and generate a positive feedback loop, amplifying both the homeostatic and inflammatory responses [
15]. Inactivation of platelets may impede this positive feedback and improve outcomes among high-risk patients.
Preclinical studies have identified beneficial effects of antiplatelet therapy in ARDS prevention, as evidenced by improved oxygenation, diminished lung edema, attenuated inflammation, and increased survival [
5]. In contrast, antiplatelet therapy also exhibited biphasic behavior in an animal study, with benefit in the early phase followed by worsening of gas exchange in the late phase [
16]. Pretreatment with antiplatelet therapy has also been reported to increase inflammation in the lung [
17]. The results of a meta-analysis based on observational studies suggested that antiplatelet therapy with aspirin was significantly associated with reduced incidence of ARDS in mixed critically ill patients [
5]. However, a recent, well-designed, randomized controlled clinical trial showed that neither the incidence of ARDS at 7 days nor the incidence of adverse effects was significantly different between antiplatelet therapy and placebo groups [
18]. Therefore, the effect of antiplatelet therapy on ARDS prevention remains controversial. The objective of the present meta-analysis was to compare the incidence of newly developed ARDS and mortality between patients with and without antiplatelet therapy, who were at a high risk of ARDS.
Discussion
Antiplatelet therapy has been suggested as an option for ARDS prevention, but its impact on patients at a high risk of ARDS remains controversial. We performed a meta-analysis of both randomized and observational studies, focusing on the potential preventive effects of antiplatelet therapy in patients at high risk of ARDS. The analysis of the observational studies suggested that antiplatelet therapy was associated with a reduced incidence of newly developed ARDS. However, the analysis of the randomized studies showed no difference between groups. Antiplatelet therapy was not significantly associated with improved mortality in randomized or observational studies.
The result of the pooled analysis of the randomized studies contradicted the conclusions of the observational studies on the incidence of newly developed ARDS. As randomized studies have a higher evidence level, this finding may suggest that antiplatelet therapy could not protect high-risk patients from ARDS. However, only two randomized studies were included, and the pooled results were mainly influenced by the study conducted by Kor et al. There are some noticeable differences between randomized and observational studies.
All observational studies recruited patients who had received antiplatelet therapy before being admitted to the hospital or the ICU. Although a propensity-adjusted analysis was performed for each observational study, potential heterogeneity among baseline characteristics in the studies cannot be ruled out. Patients on pre-hospital antiplatelet therapy were older and had more comorbidities [
11,
31,
33,
34]. Antiplatelet therapy is widely used for secondary prevention of malignant cardiovascular events in older patients with atherosclerotic vascular disease. Atherosclerosis, which is regarded as a chronic low-grade systemic inflammation, may predispose patients to excessive acute inflammation and may increase resistance to inflammation-associated cytokine production and organ failure [
37]. A history of vascular disease had an additional benefit on hospital outcomes [
37]. In the well-designed randomized studies conducted by Kor et al., potential cofounding effects of pre-hospital use of antiplatelet therapy were mitigated by excluding patients who received antiplatelet therapy at the time of hospitalization [
18]. Additionally, the incidence of ARDS in patients who discontinued antiplatelet therapy during hospitalization was not significantly different from that in patients who continued antiplatelet therapy [
31]. These findings implied that long-term pre-hospital antiplatelet therapy may protect high-risk patients from ARDS, but this benefit was not evident when patients received antiplatelet therapy after the onset of risk factors. Pre-hospital antiplatelet therapy may protect patients by suppressing platelet aggregation before initial insults occur, but the protective effect may be compromised if this process has already been triggered.
Use of a low dose of 81 mg of aspirin in randomized studies did not significantly reduce the incidence of ARDS [
18]. Four of seven observational studies included patients with antiplatelet therapy other than aspirin. A subgroup analysis of the observational studies indicated that patients who used aspirin only had a lower risk of developing ARDS compared with patients using mixed medications. Most patients in the observational studies used low-dose aspirin (81-100 mg), but the data on dosage were insufficient for subgroup analysis. It is reasonable to assume that aspirin will be a prospective treatment. Previous studies have proven that low-dose aspirin is more potent in inhibiting cyclooxygenase I (COX I) than cyclooxygenase II (COX II) [
38,
39]; the former is responsible for normal homeostatic processes and the latter inhibits inflammation. Although low-dose aspirin has also been shown to have anti-inflammatory effects due to aspirin-induced lipoxin formation, high-dose aspirin may be more effective in preventing ARDS as all preclinical studies showed beneficial effects of high-dose aspirin in ARDS [
5]. Since high-dose aspirin may be related to an increased risk of bleeding, it should be considered with caution pending further clinical investigation.
In another randomized pilot study performed by Vincent et al., patients with circulatory shock received aspirin plus dipyridamole versus aspirin plus placebo [
30]. The active comparator was dipyridamole and was therefore included in our analysis. As a small pilot study, they focused on a group of patients with circulatory shock, which is a common risk factor for ARDS in critically ill patients. This study included a relatively large number of patients presenting with hemorrhagic shock, but arterial hypotension was corrected in less than 12 h to avoid coagulation abnormalities in severe or prolonged states of shock. Considering that including patients with hemorrhagic shock and trauma may be confounding, we performed a subgroup analysis on studies with and without patients with shock or trauma. This analysis revealed a slightly greater effect on the decreased incidence of ARDS compared with the overall analysis (0.61 versus 0.68); however, the on pooled analysis of the studies of patients with shock or trauma, the decreased incidence of ARDS was no longer significant (
p = 0.062). Continuing antiplatelet therapy in patients without hemorrhage may be safe, but antiplatelet therapy in patients with a risk of hemorrhage may be risky.
The present analysis extends the findings of a recent meta-analysis conducted by Panka et al. in which similar inclusion and exclusion criteria were applied [
5]. In observational studies, antiplatelet therapy was associated with a reduced incidence of ARDS but not of mortality. A previous meta-analysis conducted by Wang et al. and Mohananey et al. revealed decreased mortality among critically ill patients receiving antiplatelet therapy [
25,
40]. Notably, they included studies that did not report the incidence of ARDS [
37,
41‐
51] and possibly included patients at a lower risk of ARDS, which may confound the result [
43,
48‐
51]. Most would expect that if patients were less likely to develop ARDS, then their risk of death would decrease. These results prompted us to review the reported adverse events in the included studies. The most concerning bleeding-related adverse events and acute kidney injury were not significantly different between patients who received or did not receive antiplatelet therapy [
11,
18]. The case-control study conducted by Ahmed et al. indicated that adverse events were strongly associated with ARDS development, as were inadequate antimicrobial therapy, mechanical ventilation with injurious tidal volumes, hospital-acquired aspiration, and the volumes of blood products transfused and fluids administered [
36]. Vincent et al. also reported that total blood transfusion volume and the ratio of thrombocytopenia was significantly higher in patients who developed ARDS [
30]. Most observational studies did not consider these important factors in their analyses [
31,
32,
34], potentially contributing to an overestimated benefit of antiplatelet therapy in ARDS prevention.
To our knowledge, this is the first study to explore the potential preventive effects of antiplatelet therapy in patients at a high risk of ARDS in both randomized and observational studies. Nonetheless, this investigation also has important limitations. First, the studies included in this meta-analysis varied considerably in the definition of ARDS, baseline patient characteristics, interventions, and study design. To address this limitation, subgroup analyses and a sensitivity analysis were performed. The subgroup analyses demonstrated that heterogeneity was mainly caused by study design and the inclusion of high-risk surgical patients, but the results remained consistent between subgroups. The sensitivity analysis indicated that the heterogeneity was significantly influenced by the study conducted by Ahmed et al., but the effect of the pooled result did not substantially change after this study was removed. Second, although the search was rigorous and comprehensive and focused on high-risk patients, interpretation of the synthesized results was limited since only two randomized studies and seven observational studies were included. Third, despite a strict selection process, the overall risk of bias was judged as unclear in the randomized studies and as medium in the observational studies. Observational studies have limitations by nature. Therefore, we used the GRADE system to assess the quality of evidence for outcomes. The quality of the evidence provided by the cohort and case-control studies was equal to the quality of the randomized studies, suggesting that the results from the observational studies should also be seriously considered. Furthermore, most of the patients included in this meta-analysis used aspirin alone, and conclusions on other antiplatelet agents should therefore be interpreted with caution. Finally, unpublished studies or conference abstracts were not included, which may be of great significance as well.